IONIS PHARMACEUTICALS INC (37)

Browse by Contract Category

Contracts

Amendment No. 2 dated July 28, 2022 to the Collaboration and License Agreement by and between the Registrant and BicycleTx Limited dated July 9, 2021. Portions of this exhibit... (Filed With SEC on November 9, 2022)
Amended and Restated Ionis Pharmaceuticals, Inc. Severance Benefit Plan (Filed With SEC on May 4, 2022)
Description of the Registrants Securities (Filed With SEC on February 25, 2022)
Form of Warrant Confirmation (Filed With SEC on April 13, 2021)
Agreement and Plan of Merger, dated as of August 30, 2020, among Akcea Therapeutics, Inc., Ionis Pharmaceuticals, Inc. and Avalanche Merger Sub, Inc (Filed With SEC on August 31, 2020)
Amendment #8 to the Research, Development and License Agreement between the Registrant, Glaxo Group Limited and Glaxosmithkline Intellectual Property Development Limited, dated... (Filed With SEC on November 6, 2019)
First Amendment dated July 8, 2022 to Factor B Development, Collaboration, Option and License Agreement by and between the Registrant, F. Hoffmann-La Roche Ltd and Hoffmann-La... (Filed With SEC on August 9, 2022)
Amendment No. 1 dated December 17, 2021 to the Collaboration and License Agreement by and between the Registrant and BicycleTX Limited dated July 9, 2021. Portions of this exhibit... (Filed With SEC on February 25, 2022)
Fourth Amended and Restated Strategic Advisory Services Agreement by and between the Registrant and B. Lynne Parshall, dated February 22, 2022 (Filed With SEC on February 25, 2022)
Forms of Performance Based Restricted Stock Unit Grant Notice and Performance Based Restricted Stock Unit Agreement for Performance Based Restricted Stock Units granted under the... (Filed With SEC on February 25, 2022)
Amended and Restated Neurology Drug Discovery and Development Collaboration, Option and License Agreement Between Ionis Pharmaceuticals, Inc., And Biogen MA Inc. Dated July 12,... (Filed With SEC on November 3, 2021)
COLLABORATION AND LICENSE AGREEMENT between BICYCLETX LIMITED and IONIS PHARMACEUTICALS, INC. Dated as of July 9, 2021 (Filed With SEC on November 3, 2021)
Non-Employee Director Compensation Policy Amended June 2, 2021 (Filed With SEC on August 4, 2021)
Non-Employee Director Compensation Policy (Filed With SEC on May 5, 2021)
[Signature page to follow] (Filed With SEC on May 5, 2021)
Form of Convertible Note Hedge Confirmation (Filed With SEC on April 13, 2021)
Indenture, dated as of April 12, 2021, by and between the Company and U.S. Bank National Association, as Trustee (Filed With SEC on April 13, 2021)
Amendment No. 3 dated December 17, 2020 to the Strategic Collaboration Agreement by and between the Registrant and AstraZeneca AB dated July 31, 2015. Portions of this exhibit... (Filed With SEC on February 24, 2021)
Side Letter dated December 31, 2020 to the New Strategic Neurology Drug Discovery and Development Collaboration, Option and License Agreement by and between the Registrant and... (Filed With SEC on February 24, 2021)
Strategic Advisory Services Agreement by and between the Registrant and Stanley T. Crooke, dated December 17, 2020 (Filed With SEC on February 24, 2021)
Third Amended and Restated Strategic Advisory Services Agreement by and between the Registrant and B. Lynne Parshall, dated February 22, 2021 (Filed With SEC on February 24, 2021)
Research Collaboration, Option and License Agreement between the Registrant and Janssen Biotech Inc. dated December 22, 2014. Portions of this exhibit have been omitted because... (Filed With SEC on February 24, 2021)
Forms of Performance Based Restricted Stock Unit Grant Notice and Performance Based Restricted Stock Unit Agreement for Performance Based Restricted Stock Units granted under the... (Filed With SEC on February 24, 2021)
First Amendment to Research Collaboration, Option and License Agreement between the Registrant and Janssen Biotech Inc. dated December 21, 2016. Portions of this exhibit have been... (Filed With SEC on February 24, 2021)
Amendment No. 2 to the Strategic Collaboration Agreement by and between the Registrant and AstraZeneca AB dated July 31, 2015 (portions of the exhibit have been omitted because... (Filed With SEC on August 5, 2020)
Side Letter dated June 11, 2020 to the Second Amended and Restated Strategic Neurology Drug Discovery and Development Collaboration, Option and License Agreement by and between... (Filed With SEC on August 5, 2020)
Letter Agreement between the Registrant, Akcea Therapeutics, Inc., and Pfizer Inc., dated October 4, 2019. Portions of this exhibit have been omitted because they are both (i) not... (Filed With SEC on March 2, 2020)
Description of the Registrants Securities (Filed With SEC on March 2, 2020)
Performance Based Restricted Stock Unit Grant Notice and Performance Based Restricted Stock Unit Agreement (Filed With SEC on January 17, 2020)
Second Amended and Restated Advisory Services Agreement dated January 9, 2020 (Filed With SEC on January 10, 2020)
Indenture, dated as of December 19, 2019, by and between Ionis Pharmaceuticals, Inc. and U.S. Bank National Association, as trustee (Filed With SEC on December 23, 2019)
Amendment No. 1 to the Neurology III Agreement between the Registrant and Biogen MA Inc., dated August 16, 2019 (portions of the exhibit have been omitted because they are both... (Filed With SEC on November 6, 2019)
Consent to Collateral Addition and Amendment to Loan Documents between the Registrant, Ionis Gazelle, LLC, Wells Fargo Bank, National Association, as Trustee for the Benefit of... (Filed With SEC on November 6, 2019)
Amendment No. 1 to Second Amended and Restated Strategic Neurology Drug Discovery and Development Collaboration, Option and License Agreement by and between the Registrant and... (Filed With SEC on August 8, 2019)
Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan (Filed With SEC on March 26, 2019)
Amended and Restated Advisory Services Agreement dated March 22, 2019 (Filed With SEC on March 26, 2019)
Factor B Development Collaboration, Option and License Agreement by and between the Registrant, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., dated October 9, 2018.... (Filed With SEC on March 1, 2019)